GlassScriptPhysician profile
Angel Salazar
NPI 1912981721
$4,065.67
in general payments reported to CMS, 2019-2025
27 companies · $786 in 2025
The $786 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $623 · 2020: $708 · 2021: $711 · 2022: $363 · 2023: $489 · 2024: $384 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,660.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $533.50 | 2019-2025 | Farxiga, Airsupra |
| Pfizer INC. | $519.73 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $424.09 | 2019-2025 | Steglatro, Steglujan, Vaxneuvance |
| Lilly USA, LLC | $396.73 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $320.62 | 2019-2025 | Trelegy Ellipta, Shingrix, Menveo |
| Abbvie INC. | $304.02 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $291.00 | 2019-2022 | |
| Novo Nordisk INC | $217.30 | 2019-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $215.99 | 2019-2025 | Jardiance |
| Alydia Health | $154.91 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $139.10 | 2020-2025 | Xifaxan, Trulance |
| Sanofi Pasteur INC. | $93.74 | 2019-2025 | |
| Amgen INC. | $87.73 | 2021-2025 | Otezla, Repatha |
| Vanda Pharmaceuticals INC. | $80.09 | 2020-2021 | |
| Inspire Medical Systems, INC. | $32.30 | 2025 | Inspire |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $31.28 | 2025 | Zoryve |
| Biohaven Pharmaceutical Holding Company LTD. | $29.52 | 2022 | |
| Incyte Corporation | $28.20 | 2025 | Opzelura |
| Cranial Technologies, INC | $27.06 | 2021 | |
| Sanofi-Aventis U.S. LLC | $23.95 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $22.66 | 2021 | |
| Alk-Abello, INC | $22.30 | 2024 | Odactra, Ragwitek, Grastek |
| Bayer Healthcare Pharmaceuticals INC. | $19.91 | 2024 | |
| Dexcom, INC. | $13.86 | 2023 | Dexcom G6 Transmitter |
| Optinose US, INC. | $12.91 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.36 | 2019 | |
| Circassia INC. | $10.81 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angel Salazar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.